187 related articles for article (PubMed ID: 33170484)
21. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
Cohen RB; Aamdal S; Nyakas M; Cavallin M; Green D; Learoyd M; Smith I; Kurzrock R
Eur J Cancer; 2013 May; 49(7):1521-9. PubMed ID: 23433846
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Van Cutsem E; Hidalgo M; Canon JL; Macarulla T; Bazin I; Poddubskaya E; Manojlovic N; Radenkovic D; Verslype C; Raymond E; Cubillo A; Schueler A; Zhao C; Hammel P
Int J Cancer; 2018 Oct; 143(8):2053-2064. PubMed ID: 29756206
[TBL] [Abstract][Full Text] [Related]
23. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
24. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC; Davis AM; Chimiczewski P; O'Malley DM; Provencher D; Vergote I; Ghamande S; Birrer MJ
Gynecol Oncol; 2020 Feb; 156(2):301-307. PubMed ID: 31870556
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
26. A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
Doi T; Takahashi S; Aoki D; Yonemori K; Hara H; Hasegawa K; Takehara K; Harano K; Yunokawa M; Nomura H; Shimoi T; Horie K; Ogasawara A; Okame S
Cancer Chemother Pharmacol; 2024 Jun; 93(6):605-616. PubMed ID: 38411735
[TBL] [Abstract][Full Text] [Related]
27. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract][Full Text] [Related]
28. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
30. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
[TBL] [Abstract][Full Text] [Related]
31. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
[TBL] [Abstract][Full Text] [Related]
32. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
33. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
34. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ; Sullivan RJ; Hwu WJ; Ramanathan RK; Adjei AA; Fong PC; Shapira-Frommer R; Tawbi HA; Rubino J; Rush TS; Zhang D; Miselis NR; Samatar AA; Chun P; Rubin EH; Schiller J; Long BJ; Dayananth P; Carr D; Kirschmeier P; Bishop WR; Deng Y; Cooper A; Shipps GW; Moreno BH; Robert L; Ribas A; Flaherty KT
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467321
[TBL] [Abstract][Full Text] [Related]
35. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Stathis A; Tolcher AW; Wang JS; Renouf DJ; Chen LC; Suttner LH; Freshwater T; Webber AL; Nayak T; Siu LL
Invest New Drugs; 2023 Jun; 41(3):380-390. PubMed ID: 37040046
[TBL] [Abstract][Full Text] [Related]
36. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
von Richter O; Massimini G; Scheible H; Udvaros I; Johne A
Br J Clin Pharmacol; 2016 Dec; 82(6):1498-1508. PubMed ID: 27483391
[TBL] [Abstract][Full Text] [Related]
37. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
38. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
39. Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
Scheible H; Kraetzer F; Marx A; Johne A; Wimmer E
Drug Metab Dispos; 2017 Feb; 45(2):174-182. PubMed ID: 27934635
[TBL] [Abstract][Full Text] [Related]
40. First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.
Wang X; Luo Z; Chen J; Chen Y; Ji D; Fan L; Chen L; Zhao Q; Hu P; Sun P; Jia Z; Guo J; Si L
BMC Med; 2023 Jan; 21(1):2. PubMed ID: 36600247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
